Page 1

MAYO CLINIC TOPLINE RESULTS FROM BOND - 003 COHORT P A MULTI - NATIONAL , SINGLE - ARM STUDY OF INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC FOR TREATMENT OF HIGH - RISK , PAPILLARY ONLY ( HG TA / T1 ) BCG - UNRESPONSIVE NON - MUSCLE INVASIVE BLADDER CANCER Paras H. Shah , MD Mayo Clinic , Rochester , MN For individual reference only . The information accessed through this QR code is intended solely for individual reference and should not be altered , modified , or reproduced in any way . Presented at the North Central Section of the American Urological Association Annual Meeting October 14 , 2026 © 2026 Mayo Foundation for Medical Education and Research | WF7883000-1